Earnings season isn't over, but the quarters from health care companies that have already reported have given us a great look at how the medical device sector's faring. Numerous companies have reported good results, but one constant remains: The cardiac rhythm management, or CRM, industry -- which handles everything from pacemakers to defibrillators -- is facing off with a tough market. Sales are falling across the industry yet again, perpetuating a worrying trait that hasn't eased up after tough results in the third quarter of 2012, as well.
Is there hope for a turnaround for companies in the CRM space, or is this an industry on the decline that you should keep your investment far away from?
Sales on the decline
Just a few years ago, the CRM market was on the rise, growing by double digits. Now, however, the market across the world has dried up -- in both the U.S. and internationally, sales are falling for CRM products.
St. Jude Medical (NYSE:STJ) has traditionally been among the powers in this business, but the company's reliance on CRM sales has come back to bite it. St. Jude's CRM division supplies around 50% of total company sales, and when that division's suffering, it's tough sledding for the company.
St. Jude's CRM department has already been on the downslide, with sales falling 4% on a constant currency in the third quarter -- a significant year-over-year slide. With the company's full-year results now out, we can see just how hard the division has fallen: CRM sales at a constant currency fell 5% year over year in St. Jude's fourth quarter, near the high end of the business' guidance, with sales down 3.5% over the course of the full year.
Fortunately, St. Jude's largest segment in the CRM business -- its ICD (or implantable cardioverter defibrillator) segment -- hasn't been hit quite as bad. Currency issues have really plagued this business, as the ICD segment only lost 2% over the course of the year at a constant currency. Falling pacemaker revenue has really hit St. Jude hard, but this company is hardly alone in its CRM troubles.
Boston Scientific (NYSE:BSX) doesn't rely as heavily on CRM sales as its rival, but its sales are no less concerning. After losing 4% in its CRM revenue for the third quarter, Boston Scientific's business dropped another 4% in Q4 for a total loss of 7% year-over-year for 2012.
Even the industry's biggest major player, Medtronic (NYSE:MDT), has witnessed its CRM business losing sales, particularly among pacemakers. Things aren't so good in this sector, but why are sales falling -- and what should you account for in the future?
What the future holds for the CRM business
The CRM market is already mature to the point of saturation in economies such as the U.S. and Europe. New patients for implantable devices will inevitably arise due to rising obesity rates and an aging population in advanced economies -- two major indicators for heart problems. However, with many patients already being treated with such devices, finding growth will remain a challenge. The Millennium Research Group has predicted little growth from the CRM market through 2016, particularly with prices falling in advanced economies.
It doesn't help that regulators and lawmakers have turned their attention to pacemakers and ICDs in recent times as well. The Department of Justice has already eyed the overuse of ICDs, particularly in patients who don't medically require an implanted device. The Centers for Medicare and Medicaid Services also launched an audit last year over the implementation of pacemakers. While all the oversight may not lead to any serious regulatory changes, the Millennium Research Group predicts that it could reduce procedural growth in coming years -- which is not what companies in the CRM area want to hear.
So, how should you play this business? Companies in the field have been looking recently to shift away from relying on CRM sales. Boston Scientific has fueled its growth in less sales-heavy businesses, such as neuromodulation and women's health. St. Jude also has pushed for growth n other divisions, and the company predicts that 2013 will be its first year that CRM revenue will make up less than 50% of total yearly sales.
St. Jude has predicted a good year ahead, and Boston Scientific's better-than-expected fourth quarter could be the turnaround sign investors have long waited for. However, your best bet out of the companies most involved in the CRM business is Medtronic. It's not as much a growth candidate as the other two, but it's a stable company that only relies on around 30% of its revenue in CRM sales.
Boston Scientific also doesn't rely too heavily on CRM, but its largest business -- interventional cardiology -- is also seeing sales on the decline. I believe this company's ultimately headed in the right direction, but keep an eye on it to see whether it can sustain this quarter's momentum. If Boston Scientific can slow or stem its losses in its CRM and interventional cardiology departments while investing more into its higher-growth segments, it'll be firmly on the right track to long-term success.
Not the market you're looking for
In all, the CRM market isn't the high-growth industry investors want to see. With a mature market and sales falling around the industry, don't expect the companies most involved here to turn falling sales into growth any time soon. That doesn't mean that firms like Boston Scientific and Medtronic are bad investments, however -- it simply means they need to focus more on higher-growth businesses while maintaining or growing market share in the CRM space. If they can't fuel growth in other areas, however, these companies could be in for a rough future.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.